Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Posted on by

The only solution for intractable cancer caused by mutations in the p53 gene Planning clinical trials targeting cancer patients with no available treatment due to p53 gene mutations SEOUL, South Korea, April 25, 2024 /PRNewswire/ — Hyundai Bioscience announced on April 25th that its…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.